Associative Professor Alaina AmmitBiography
Associate Professor Alaina Ammit is Associate Dean (Research and Innovation) at the Faculty of Pharmacy, University of Sydney. She has earned an international reputation for her work elucidating pro-inflammatory signalling pathways in asthma and airway remodelling.
Alaina completed both her MSc and PhD studies in reproductive medicine through the University of Sydney, at the Human Reproduction Unit, Royal North Shore Hospital. In 1996, Alaina changed fields from IVF to asthma and joined the Respiratory Research Group at the University of Sydney and was awarded the Martin Hardie Fellowship from the Asthma Foundation of NSW. In 1997, she then went on to a post-doctoral position at the University of Pennsylvania in Philadelphia, USA, supported by a National Health & Medical Research Council CJ Martin Fellowship.
Returning to Australia in 2001, Alaina took up an academic position at the University of Sydney and combines investigating the basic mechanisms of inflammation in asthma with her research team, teaching prospective Pharmacists, and serving as Associate Dean (Research & Innovation) for the Faculty of Pharmacy.
Alaina loves being a medical researcher! She enjoys constantly learning and discovering by performing research in an area that will ultimately help human health. She is enthusiastic and passionate about the exciting medical research happening in the world today. Always keen to promote a greater awareness and understanding of medical research within the community, Alaina convened the National ASMR Medical Research Week® (2003-2005) while she a Director of the Australian Society of Medical Research (ASMR), the peak professional society representing Australian Health and Medical Research.
In recognition of her public outreach activities and commitment to science promotion, Alaina was awarded a 2006 NSW/ACT Young Tall Poppy Science Award for outstanding achievements in science.
Asthma is a widespread chronic health problem. Airway remodelling underlies asthma, but unfortunately, the pharmacotherapy currently available for combating remodelling has had limited success. We need to understand how to control airway remodelling to be able to improve treatments for asthma. With our work we will increase our knowledge of the mechanistic basis of asthma.
It is our hope that the elucidation of novel molecular strategies and drug candidates will serve as a future pharmacotherapeutic approach to treating and preventing airway remodelling.